ANTI-COLOR FADING AND FRAGRANCE PROTECTION COMPOSITIONS

Abstract

The present disclosure is directed to stabilizing compositions comprising a mixture of three or more ultraviolet filters. The disclosed compositions are useful for stabilizing the color and the fragrance of formulations, including cosmetic formulations and household products.

Claims

1. A method for stabilizing the color and fragrance of a cosmetic against the effect of UV radiation comprising the steps of: preparing a UV absorbing composition comprising: (a) at least one cinnamate-containing compound or cinnamate-containing derivative compound, said cinnamate-containing compound or cinnamate-containing derivative compound absorbing radiation in the UV region; (b) at least one triazine-containing compound or triazine-containing derivative compound, said triazine-containing compound or triazine-containing derivative compound absorbing radiation in the UVB region; and (c) at least one dibenzoylmethane-containing compound or dibenzoylmethane-containing derivative compound, said dibenzoylmethane-containing compound or dibenzoylmethane-containing derivative compound absorbing radiation in the UV region; and incorporating the UV absorbing composition into a cosmetic formulation.

2. The method of claim 1, wherein the UV absorbing composition comprises about 5.0 to about 90.0% by weight of compound (a); about 5.0 to about 90.0% by weight of compound (b); and about 5.0 to about 90.0% by weight of compound (c).

3. The method of claim 1, wherein compound (a) comprises Uvasorb HEB, CAS [154702-15-5]; compound (b) comprises Octyl methoxycinnamate, CAS [5466-77-3]; and compound (c) comprises Avobenzone, CAS [70356-09-1].

4. The method of claim 1, wherein the UV absorbing composition further comprises (d) one or more surfactants.

5. The method of claim 4, wherein the UV absorbing composition comprises a combination of: about 1.0 to about 50.0% by weight of compound (a); about 1.0 to about 50.0% by weight of compound (b); about 1.0 to about 50.0% by weight of compound (c); and about 50.0 to about 90.0% by weight of compound (d).

6. The method of claim 4, wherein the composition comprises a combination of: about 1.0 to about 20.0% by weight of Uvasorb HEB, CAS [154702-15-5]; about 1.0 to about 20.0% by weight of Octyl methoxycinnamate, CAS [5466-77-3]; about 1.0 to about 20.0% by weight of Avobenzone, CAS [70356-09-1]; and about 20.0 to about 80.0% by weight of compound (d).

7. A method for stabilizing the color and fragrance of a cosmetic against the effect of UV radiation comprising the steps of: preparing a UV absorbing composition comprising: (a) at least one UV absorbing compound, said UV absorbing compound comprising a cinnamate-containing compound or a cinnamate-containing derivative compound; (b) at least one UV absorbing compound absorbing in the UVB region, said UV absorbing compound absorbing in the UVB region comprising a triazines-containing compound or a triazine-containing derivative compound; and (c) at least one UV absorber compound absorbing in the UVA region, said UV absorber compound absorbing in the UVA region comprising a triazine-containing compound or a triazine derivative compound; and incorporating the UV absorbing composition into a cosmetic formulation.

8. The method of claim 7, wherein the UV absorbing composition comprises a combination of: about 5.0 to about 90.0% by weight of compound (a); about 5.0 to about 90.0% by weight of compound (b); and about 5.0 to about 90.0% by weight of compound (c).

9. The method of claim 7, wherein compound (a) comprises Uvasorb HEB, CAS [154702-15-5]; compound (b) comprises Octyl methoxycinnamate, CAS [5466-77-3]; and compound (c) comprises Uvasorb K2A, CAS [288254-16-0].

10. The method of claim 7, wherein the UV absorbing composition further comprises: (d) at least one surfactant.

11. The method of claim 7, wherein the UV absorbing compound comprises a combination of: about 1.0 to about 50.0% by weight of compound (a); about 1.0 to about 50.0% by weight of compound (b); about 1.0 to about 50.0% by weight of compound (c); and about 50.0 to about 90.0% by weight of compound (d).

12. The composition of claim 10, wherein the composition comprises a combination of: about 1.0 to about 20.0% by weight of Uvasorb HEB, CAS [154702-15-5]; about 1.0 to about 20.0% by weight of Octyl methoxycinnamate, CAS [5466-77-3]; about 1.0 to about 20.0% by weight of Uvasorb K2A, CAS [288254-16-0]; and about 20.0 to about 80.0% of one or a mixture of surfactants.

13. A composition, comprising: (a) at least one UV absorbing compound comprising a cinnamate-containing compound or a cinnamate-containing derivative compound; (b) at least one IV absorbing compound absorbing in the UVB region, said UV absorbing compound absorbing in the UVB region comprising a triazine-containing compound or a triazine-containing derivative compound; and (c) at least one UV absorbing compound comprising a dibenzoylmethane-containing compound or a dibenzoylmethane-containing derivative compound.

14. The composition of claim 13, wherein the composition comprises a combination of: about 5.0 to about 90.0% by weight of compound (a); about 5.0 to about 90.0% by weight of compound (b); and about 5.0 to about 90.0% by weight of compound (c).

15. The composition of claim 13, comprising a combination of: about 1.0 to about 50.0% by weight of compound (a); about 1.0 to about 50.0% by weight of compound (b); about 1.0 to about 50.0% by weight of compound (c); and about 50.0 to about 90.0% by weight of compound (d).

16. The composition of claim 13, wherein compound (a) comprises Uvasorb HEB, CAS [154702-15-5]; compound (b) comprises Octyl methoxycinnamate, CAS [5466-77-3]; and compound (c) comprises Avobenzone, CAS [70356-09-1].

17. The composition of claim 13, wherein the composition further comprises: (d) one or more surfactants.

18. A composition, comprising: (a) at least one UV absorbing compound comprising a cinnamate-containing compound or cinnamate-containing derivative compound; (b) at least one UV absorbing compound absorbing radiation in the UVB region, said UV absorbing compound absorbing radiation in the UVB region comprising a triazine-containing compound or a triazine-containing derivative compound; and (c) at least one UV absorbing compound absorbing radiation in the UVA region, said UV absorbing compound absorbing radiation in the UVA region comprising a triazine-containing compound or a triazine-containing derivative compound.

19. The composition of claim 18, further comprising (d) one or more surfactants.

20. The composition of claim 19, comprising a combination of: about 1.0 to about 50.0% by weight of compound (a); about 1.0 to about 50.0% by weight of compound (b); about 1.0 to about 50.0% by weight of compound (c); and about 50.0 to about 90.0% by weight of compound (d).

21. The composition of claim 18, comprising a combination of: about 1.0 to about 20.0% by weight of Uvasorb HEB, CAS [154702-15-5]; about 1.0 to about 20.0% by weight of Octyl methoxycinnamate, CAS [5466-77-3]; about 1.0 to about 20.0% by weight of Uvasorb K2A, CAS [288254-16-0]; and about 20.0 to about 80.0% of one or more surfactants.

22. The composition of claim 18, comprising a combination of: about 5.0 to about 90.0% by weight of compound (a); about 5.0 to about 90.0% by weight of compound (b); and about 5.0 to about 90.0% by weight of compound (c).

23. The composition of claim 18, wherein: compound (a) comprises Uvasorb HEB, CAS [154702-15-5]; compound (b) comprises Octyl methoxycinnamate, CAS [5466-77-3]; and compound (c) compound Uvasorb K2A, CAS [288254-16-0].

24. A cosmetic formulation or cosmetic precursor formulation comprising the composition of claim 18.

25. A household product formulation or household product precursor formulation comprising the composition of claim 18.

Description

DETAILED DESCRIPTION

[0076] According to one aspect, the present disclosure provides a stabilizer composition comprising a combination of at least one UV filter derivative of s-triazine (defined as COMPONENT A) not known to have been used in combination with one or more UV filter compounds defined as COMPONENT B.

[0077] Preferred compounds for COMPONENT A comprise:

[0078] Uvasorb HEB, CAS [154702-15-5]

[0079] Preferred compounds for COMPONENT B comprise:

[0080] p-Aminobenzoic Acid, CAS [150-13-0]

[0081] Padimate O, CAS [21245-02-3]

[0082] Ensulizole, CAS [27503-81-7]

[0083] Cinoxate, CAS [104-28-9]

[0084] Dioxybenzone, CAS [131-53-3]

[0085] Oxybenzone, CAS [131-57-7]

[0086] Homosalate, CAS [118-56-9]

[0087] Menthyl anthranilate, CAS [134-09-8]

[0088] Octocrylene, CAS [6197-30-4]

[0089] Octyl methoxycinnamate, CAS [5466-77-3]

[0090] Octyl salicylate, CAS [118-6-5]

[0091] Sulisobenzone, CAS [4065-45-6]

[0092] Trolamine salicylate, CAS [2174-16-5]

[0093] Avobenzone, CAS [70356-09-1]

[0094] Ecamsule, CAS [92761-26-7]

[0095] Titanium dioxide, CAS [13463-67-7]

[0096] Zinc oxide, CAS [1314-13-2]

[0097] 4-Methylbenzylidene camphor, CAS [36861-47-9]

[0098] Tinosorb M, CAS [103597-45-1]

[0099] Bemotrizinol, CAS [187393-00-6]

[0100] Bisdisulizole disodium, CAS [180898-37-7]

[0101] Mexoryl XL, CAS [155633-54-8]

[0102] Uvinul DS 49, CAS [3121-60-6]

[0103] Uvinul T150, CAS [88122-99-0]

[0104] Uvinul A Plus, CAS [302776-68-7]

[0105] Amiloxate, CAS [71617-10-2]

[0106] Uvasorb K2A, CAS [288254-16-0]

[0107] Parsol LSX,

[0108] Derivative of the PABA,

[0109] Derivative of the benzimidazole,

[0110] Derivative of the cinnamic acid,

[0111] Derivative of the benzophenone,

[0112] Derivative of the salicylic acid,

[0113] Derivative of the anthranilic acid,

[0114] Derivative of the cyanoacrylic acid,

[0115] Derivative of the dibenzoylmethane,

[0116] Derivative of the terephthalidene dicamphor,

[0117] Derivative of the benzylidene camphor,

[0118] Derivative of the benzotriazole,

[0119] Derivative of the s-triazine,

[0120] Derivative of the silicone and

[0121] Derivative of the acrylic acid.

[0122] Aspects of the present disclosure therefore provide stabilizer compositions as follows:

[0123] Composition 1

[0124] Aspects of the present disclosure contemplate a mixture of one COMPONENT A compound with one COMPONENT 1 compound comprising the following ranges:

[0125] COMPONENT A—5.0-90.0% of a s-triazine derivative and

[0126] COMPONENT B—5.0-90.0% of a s-triazine derivative.

[0127] In a further aspect. COMPOSITION 1 comprises:

[0128] COMPONENT A—5.0-90.0% of Uvasorb HEB, CAS [154702-15-5] and

[0129] COMPONENT B—5.0-90.0% of Uvasorb K2A, CAS [288254-16-0].

[0130] In another aspect, COMPOSITION 1 comprises:

[0131] COMPONENT A—70.0% of Uvasorb HEB, CAS [154702-15-5] and

[0132] COMPONENT B—30.0% of Uvasorb K2A, CAS [288254-16-0].

[0133] Composition 2

[0134] Aspects of the present disclosure contemplate a mixture of one COMPONENT A compound with two COMPONENT B compounds comprising the following ranges:

[0135] COMPONENT A—5.0-90.0% of a s-triazine derivative,

[0136] COMPONENT B—5.0-90.0% of a s-triazine derivative and

[0137] COMPONENT B—5.0-90.0% of a cinnamate derivative.

[0138] One further aspect contemplates COMPOSITION 2 comprising:

[0139] COMPONENT A—5.0-90.0% of Uvasorb HEB, CAS [154702-15-5],

[0140] COMPONENT B—5.0-90.0% of Uvasorb K2A, CAS [288254-16-0] and

[0141] COMPONENT B—5.0-90.0% of Octyl methoxycinnamate, CAS [5466-77-3].

[0142] In a still further aspect COMPOSITION 2 comprises:

[0143] COMPONENT A—15.0% of Uvasorb HEB, CAS [154702-15-5],

[0144] COMPONENT B—15.0% of Uvasorb K2A, CAS [288254-16-0] and

[0145] COMPONENT B—70.0% of Octyl methoxycinnamate, CAS [5466-77-3].

[0146] Composition 3

[0147] Aspects of the present disclosure contemplate a mixture of one COMPONENT A compound with two COMPONENT B compounds comprising the following ranges:

[0148] COMPONENT A—5.0-90.0% of a s-triazine derivative,

[0149] COMPONENT B—5.0-90.0% of a dibenzoylmethane derivative and

[0150] COMPONENT B—5.0-90.0% of a cinnamate derivative.

[0151] In one aspect, COMPOSITION 3 comprises:

[0152] COMPONENT A—5.0-90.0% of Uvasorb HEB, CAS [154702-15-5],

[0153] COMPONENT B—5.0-90.0% of Avobenzone, CAS [70356-09-1] and

[0154] COMPONENT B—5.0-90.0% of Octyl methoxycinnamate, CAS [5466-77-3].

[0155] In a further aspect, COMPOSITION 3 comprises:

[0156] COMPONENT A—20.0% of Uvasorb HEB, CAS [154702-15-5],

[0157] COMPONENT B—20.0% of Avobenzone, CAS [70356-09-1] and

[0158] COMPONENT B—60.0% of Octyl methoxycinnamate, CAS [5466-77-3].

[0159] Composition 4

[0160] Aspects of the present disclosure further contemplate a mixture of one COMPONENT A compound with three COMPONENT B compounds comprising the following ranges:

[0161] COMPONENT A—5.0-90.0% of a s-triazine derivative,

[0162] COMPONENT B—5.0-90.0% of a dibenzoylmethane derivative,

[0163] COMPONENT B—5.0-90.0% of a cinnamate derivative and

[0164] COMPONENT B—5.0-90.0% of a s-triazine derivative.

[0165] In a further aspect, COMPOSITION 4 comprises:

[0166] COMPONENT A—5.0-90.0% of Uvasorb HEB, CAS [154702-15-5],

[0167] COMPONENT B—5.0-90.0% of Avobenzone, CAS [70356-09-1],

[0168] COMPONENT B—5.0-90.0% of Octyl methoxycinnamate, CAS [5466-77-3],

[0169] COMPONENT B—5.0-90.0% of Uvasorb K2A, CAS [288254-16-0].

[0170] In another aspect, COMPOSITION 4 comprises:

[0171] COMPONENT A—20.0% of Uvasorb HEB, CAS [154702-15-5],

[0172] COMPONENT B—5.0% of Avobenzone, CAS [70356-09-1],

[0173] COMPONENT B—65.0% of Octyl methoxycinnamate, CAS [5466-77-3],

[0174] COMPONENT B—10.0% of Uvasorb K2A, CAS [288254-16-0].

[0175] Composition 5

[0176] Aspects of the present disclosure contemplate a mixture of one COMPONENT A with three COMPONENT B comprising the following ranges:

[0177] COMPONENT A—5.0-90.0% of a s-triazine derivative,

[0178] COMPONENT B—5.0-90.0% of a benzophenone derivative,

[0179] COMPONENT B—5.0-90.0% of a cinnamate derivative and

[0180] COMPONENT B—5.0-90.0% of a s-triazine derivative.

[0181] In a further aspect, COMPOSITION 5 comprises:

[0182] COMPONENT A—5.0-90.0% of Uvasorb HEB, CAS [154702-15-5],

[0183] COMPONENT B—5.0-90.0% of Uvinul A Plus, CAS [302776-68-7].

[0184] COMPONENT B—5.0-90.0% of Octyl methoxycinnamate, CAS [5466-77-3],

[0185] COMPONENT B—5.0-90.0% of Uvasorb K2A, CAS [288254-16-0].

[0186] In another aspect, COMPOSITION 5 comprises:

[0187] COMPONENT A—10.0% of Uvasorb HEB, CAS [154702-15-5],

[0188] COMPONENT B—10.0% of Uvinul A Plus, CAS [302776-68-7],

[0189] COMPONENT B—70.0% of Octyl methoxycinnamate, CAS [5466-77-3],

[0190] COMPONENT B—10.0% of Uvasorb K2A, CAS [288254-16-0].

[0191] The above compositions are prepared as follows:

Example 1

[0192] We prepared a stabilizing composition comprising 70% of Uvasorb HEB by mass and 30% of Uvasorb K2A by mass, according to the following protocol. In a nitrogen blanketed flask, 70 g of Uvasorb HEB was loaded with heat is applied to reach 140° C. once the Uvasorb HEB was molten and fluid a gentle agitation was started. A 30 g sample of Uvasorb K2A was loaded. The mixture was heated and maintained at 140° C. with stirring until obtaining a clear liquid. The homogeneous mixture was flaked and milled obtaining a whitish powder.

Example 2

[0193] A stabilizing composition was prepared comprising 70% of Octyl methoxy cinnamate by mass, 15% of Uvasorb HEB by mass and 15% of Uvasorb K2A by mass, according to the following protocol. In a flask, were introduced 70 g Octyl methoxy cinnamate, 15 g of Uvasorb HEB and 15 g of Uvasorb K2A. The mixture thus obtained was heated to 60° C. with stirring until obtaining a clear liquid.

Example 3

[0194] A stabilizing composition was prepared comprising 60% of Octyl methoxy cinnamate by mass, 20% of Uvasorb HEB by mass and 20% of Avobenzone by mass, according to the following protocol. In a flask, were introduced 60 g Octyl methoxy cinnamate, 20 g of Uvasorb HEB and 20 g of Avobenzone. The mixture thus obtained was heated to 60° C. with stirring until obtaining a clear liquid.

Example 4

[0195] A stabilizing composition was prepared comprising 65% of Octyl methoxy cinnamate by mass, 20% of Uvasorb HEB by mass, 10% of Uvasorb K2A and 5% of Avobenzone by mass, according to the following protocol. In a flask, were introduced 65 g Octyl methoxy cinnamate, 20 g of Uvasorb HEB, 10 g of Uvasorb K2A and 5 g of Avobenzone. The mixture thus obtained was heated to 60° C. with stirring until obtaining a clear liquid.

Example 5

[0196] A stabilizing composition was prepared comprising 70% of Octyl methoxy cinnamate by mass, 10% of Uvasorb HEB by mass, 10% of Uvasorb K2A and 10% of Uvinul A Plus by mass, according to the following protocol. In a flask, were introduced 70 g Octyl methoxy cinnamate, 10 g of Uvasorb HER, 10 g of Uvasorb K2A and 10 g of Uvinul A Plus. The mixture thus obtained was heated to 60° C. with stirring until obtaining a clear liquid.

Formulations

[0197] The compositions of Example 1, Example 2. Example 3, Example 4 and Example 5 were compared to known and commercially available anti-color fading compositions, (e.g. COVABSORB (WO2006/005846)), in cosmetic water-based and non-water-based formulations containing dyes and perfumes.

Formula A—Shampoo

[0198] Tables 1 and 2 report the compositions of shampoo formulas:

TABLE-US-00001 TABLE 1 A1 A2 A3 A4 A5 A6 A7 TEXAPON NSA 30% 30% 30% 30% 30% 30% 30% COCOAMIDOPROPYLBETAINE 10% 10% 10% 10% 10% 10% 10% FD & C Red 40 0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   Example 1  1% — — — — — — Example 2 —  1% — — — — — Example 3 — —  1% — — — — Example 4 — — —  1% — — — Example 5 — — — —  1% — — COVABSORB — — — — —  1% — Water to 100% to 100% to 100% to 100% to 100% to 100% to 100% pH 5.1 5.2 5.5 4.9 5.1 5 5.3

TABLE-US-00002 TABLE 2 A8 A9 A10 A11 A12 A13 A14 TEXAPON NSA 30% 30% 30% 30% 30% 30% 30% COCOAMIDOPROPYLBETAINE 10% 10% 10% 10% 10% 10% 10% FD & C Red 40 0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   Example 1 0.65%   — — — — — — Example 2 — 0.80%   — — — — — Example 3 — — 0.80%   — — — — Example 4 — — — 0.75%   — — — Example 5 — — — — 0.87%   — — COVABSORB — — — — — 1.00%  — Water to 100% to 100% to 100% to 100% to 100% to 100% to 100% pH 5.2 5.2 4.9 5.1 5.2 5.3 5.3

[0199] The compounds of the Formulas A7 and A14 did not contain any stabilizing compositions and they were used as control.

Formula B—Oil Based

[0200] Tables 3 and 4 report the compositions of oil based formulas:

TABLE-US-00003 TABLE 3 B1 B2 B3 B4 B5 B6 B7 D & C Red 17 0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   Example 1  1% — — — — — — Example 2 —  1% — — — — — Example 3 — —  1% — — — — Example 4 — — —  1% — — — Example 5 — — — —  1% — — COVABSORB — — — — —  1% — Castor Oil to 100% to 100% to 100% to 100% to 100% to 100% to 100%

TABLE-US-00004 TABLE 4 B8 B9 B10 B11 B12 B13 B14 D & C Red 17 0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   Example 1 0.65%   — — — — — — Example 2 — 0.80%   — — — — — Example 3 — — 0.80%   — — — — Example 4 — — — 0.75%   — — — Example 5 — — — — 0.87%   — — COVABSORB — — — — —  1% — Castor Oil to 100% to 100% to 100% to 100% to 100% to 100% to 100%

[0201] The compounds of the Formulas B7 and B14 did not contain any stabilizing compositions and they were used as control.

Formula C—Perfume

[0202] Tables 5 and 6 is reported the compositions of perfume formulas:

TABLE-US-00005 TABLE 5 C1 C2 C3 C4 C5 C6 C7 Ethylvanillin  3%  3%  3%  3%  3%  3%  3% FD & C Red 40 0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   0.001%   Example 1  1% — — — — — — Example 2 —  1% — — — — — Example 3 — —  1% — — — — Example 4 — — —  1% — — — Example 5 — — — —  1% — — COVABSORB — — — — —  1% — Ethanol 96% to 100% to 100% to 100% to 100% to 100% to 100% to 100%

TABLE-US-00006 TABLE 6 C8 C9 C10 C11 C12 C13 C14 Ethylvanillin    3%    3%    3%    3%    3%    3%    3% FD & C Red 40 0.001% 0.001% 0.001% 0.001% 0.001% 0.001% 0.001% Example 1  0.65% — — — — — — Example 2 —  0.80% — — — — — Example 3 — —  0.80% — — — — Example 4 — — —  0.75% — — — Example 5 — — — —  0.87% — — COVABSORB — — — — — —  1% — Ethanol 96% to 100% to 100% to 100% to 100% to 100% to 100% to 100%

[0203] The compounds of the Formulas C7 and C14 did not contain any stabilizing compositions and they were used as controls.

Formula D—Water Based Formula

[0204] Tables 7 and 8 is report the compositions of water based formulas:

TABLE-US-00007 TABLE 7 D1 D2 D3 D4 D5 D6 D7 FD & C Blue 1 0.001% 0.001% 0.001% 0.001% 0.001% 0.001% 0.001% Example 1    1% — — — — — — Example 2 —    1% — — — — — Example 3 — —    1% — — — — Example 4 — — —  — 1% — — — Example 5 — — — —    1% — — COVABSORB — — — — —    1%% — PPG-26-Buteth-26    2%    2%    2%    2%    2%    2%    2% PEG-40 Hydrogenated castor oil    2%    2%    2%    2%    2%    2%    2% Water to 100% to 100% to 100% to 100% to 100% to 100% to 100% pH 4.9 5.1 5.2 5.1 5.2 4.9 5.2

TABLE-US-00008 TABLE 8 D8 D9 D10 D11 D12 D13 D14 FD & C Blue 1 0.001% 0.001% 0.001% 0.001% 0.001% 0.001% 0.001% Example 1  0.65% — — — — — — Example 2 —  0.80% — — — — — Example 3 — —  0.81% — — — — Example 4 — — —  0.75% — — — Example 5 — — — —  0.87% — — COVABSORB — — — — —    1% — PPG-26-Buteth-26    2%    2%    2%    2%    2%    2%    2% PEG-40 Hydrogenated castor oil    2%    2%    2%    2%    2%    2%    2% Water to 100% to 100% to 100% to 100% to 100% to 100% to 100% pH 5.1 4.8 5.1 5.2 5.2 5.1 5.3

[0205] The compounds of the Formulas D7 and D14 did not contain any stabilizing compositions as they were used as controls.

Colorimetric Measures and WOM

[0206] The cosmetic formulations described above were exposed to UV rays in a WOM ATLAS Ci4000 apparatus and monitored over time during the exposure. The stabilizing effect of the compositions was demonstrated by measurement of the decay of the absorbance at the max wavelength of absorbance between 400 and 720 nm at the max wavelength characteristic of the relative dye, or by measuring the time of exposure to obtain the same absorbance at the max wavelength characteristic of the relative dye. Both stabilizing effects were compared to the known and commercially available anti-color fading compositions, (e.g. COVABSORBI (WO2006/005846)). The colorimetric strength (CS) of each cosmetic formulation is determined by the following mathematical formula:

CS=(Amax exposed/Amax control)×100

[0207] CS is the colorimetric strength expressed in percent, Amax control is the max absorbance of the control not exposed at the max wavelength characteristic of the relative dye and Amax exposed is the absorbance of the formula after the time of exposure. A spectrophotometer UV/Vis Perkin Elmer Lambda 25 was used to determine the absorbance prior, during and after the exposure. CS equal to 100% when Amax exposed=Amax control, evidencing that the dye has been stabilized, CS equal to 0 when the Amax exposed is zero and the dye is completely deteriorated.

[0208] The cosmetic formulations of Tables 2, 4, 6 and 8 were exposed to the UV rays into a WOM ATLAS Ci4000 for 24 hours. I was surprisingly found 15-35% less amount of stabilizing composition shown in Example 1, 2, 3, 4 and 5 was required to obtain characteristics substantially equivalent to or better than known commercial available COVABSORB (WO 2006/005846). Such characteristics include protection from UV radiation.

TABLE-US-00009 TABLE 9 A8 A9 A10 A11 A12 A13 A14 CS 88% 86% 86% 87% 85% 85% 0% B8 B9 B10B B11 B12 B13 B14 CS 87% 85% 87% 84% 83% 82% 0% C8 C9 C10 C11 C12 C13 C14 CS 90% 86% 87% 86% 86% 86% 0% D8 D9 D10 D11 D12 D13 D14 CS 84% 83% 84% 82% 81% 80% 0%

[0209] According to the result shown in Table 9, the compounds of the formulas A8, B8, C8 and D8 comprises 35% less amount of stabilizing composition than compounds of the formulas A13, B13, C13 and D13 (COVABSORB) to obtain at least substantially equivalent levels of UV radiation protection.

[0210] The compounds of the formulas A9, B9, C9 and D9 comprised 20% less amount of stabilizing composition than A13, B13, C13 and D13 (COVABSORB) to obtain at least substantially equivalent levels of UV radiation protection.

[0211] The compounds of the formulas A10, B10, C10 and D10 comprised 20% less amount of stabilizing composition than A13, B13, C13 and D13 (COVABSORB) to obtain at least substantially equivalent levels of UV protection.

[0212] The compounds of the formulas A11, B11, C11 and D11 comprised 25% less amount of stabilizing composition than A13, B13, C13 and D13 (COVABSORB) to obtain at least substantially equivalent levels of UV protection.

[0213] The compounds of the formulas A12, B12, C12 and D12 comprised 13% less amount of stabilizing composition than A13, B13, C13 and B13 (COVABSORB) to obtain at least substantially equivalent levels of UV protection.

[0214] The cosmetic formulation of the Table 1, 3, 5 and 7 were exposed to the UV rays in a WOM ATLAS Ci4000. The CS was determined for all the cosmetic formulations every 4 hours. It was surprisingly found that the stabilizing composition of Examples 1, 2, 3, 4 and 5 remained effective for UV radiation protection for an increased duration of from about 15 to 50% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain the same CS.

TABLE-US-00010 TABLE 10 A1 A2 A3 A4 A5 A6 A7 Hours 36 30 31 31 27 24 0% CS.sub.24th B1 B2 B3 B4 B5 B6 B7 Hours 35 31 30 31 28 24 0% CS.sub.24th C1 C2 C3 C4 C5 C6 C7 Hours 37 30 30 32 28 24 0% CS.sub.24th D1 D2 D3 D4 D5 D6 D7 Hours 36 29 31 32 27 24 0% CS.sub.24th

[0215] According to Table 10, the formulas A1, B1, C1 and D1 remained effective for UV radiation protection for an increased duration of from about 15 to 50% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain a substantially equivalent level of UV radiation protection.

[0216] The compounds of the formulas A2, B2, C2 and D2 remained effective for UV radiation protection for an increased duration of from about 25% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain a substantially equivalent CS.

[0217] The compounds of the formulas A3, B3, C3 and D3 remained effective for UV radiation protection for an increased duration of from about 25% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain a substantially equivalent level of protection.

[0218] The compounds of the formulas A4, B4, C4 and D4 remained effective for UV radiation protection for an increased duration of from about 30% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain a substantially equivalent level of protection.

[0219] The compounds of formulas A5, B5, C5 and D5 remained effective for UV radiation protection for an increased duration of from about 15% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain a substantially equivalent level of protection.

HPLC Measures and WOM

[0220] The cosmetic formulations C (C1 to C14) described above were exposed to UV rays in a WOM ATLAS Ci4000 apparatus and monitored over time during the exposure. The stabilizing effect of the composition was demonstrated by HPLC, quantifying by mass the amount of the Ethylvanillin in the formulation prior, during and after the exposure to UV rays. The UV stabilizing effects were compared to the known, commercially available anti-color fading compositions, (e.g. COVABSORB (WO2006/005846)). An HPLC Agilent Technologies series 1200 with UV-Vis detector was used to quantify the amount of Ethylvanillin present in the formulations.

[0221] The cosmetic formulations of Table 6 were exposed to the UV rays in a WOM ATLAS Ci4000 for 24 hours and it was surprisingly found that a reduced amount of from about 15 to about 35% of stabilizing compositions of Example 1, 2, 3, 4 and 5 was required to achieve a substantially equivalent level of UV radiation protection (duration) as compared to the known, commercially available COVABSORB (WO 2006/005846).

TABLE-US-00011 TABLE 11 C8 C9 C10 C11 C12 C13 C14 Ethyl- 2.72% 2.69% 2.73% 2.71% 2.65% 2.70% 0% vanil- lin % w/w

[0222] The compounds of formula C8 used 35% less amount of stabilizing composition than C13 (COVABSORB) to obtain a substantially equivalent level of UV protection.

[0223] The compounds of formula C9 used 20% less amount of stabilizing composition than C13 (COVABSORB) to obtain a substantially equivalent level of UV protection.

[0224] The compounds of formula C10 used 20% less amount of stabilizing composition than C13 (COVABSORB) to obtain a substantially equivalent level of UV protection.

[0225] The compounds of formula C11 used 25% less amount of stabilizing composition than C13 (COVABSORB) to obtain a substantially equivalent level of UV protection.

[0226] The compounds of formula C12 used 13% less amount of stabilizing composition than C13 (COVABSORB) to obtain a substantially equivalent level of UV protection.

[0227] The cosmetic formulations presented in Table 5 were exposed to the UV rays in a WOM ATLAS Ci4000. The Ethylvanillin content was determined by HPLC for the cosmetic formulations every 4 hours. It was surprisingly found that stabilizing compositions presented in Example 1, 2, 3, 4 and 5 remain effective for UV radiation protection for an increased duration of from about 15 to about 50% as compared to known, commercially available COVABSORB (WO 2006/005846) to obtain a substantially equivalent CS.

TABLE-US-00012 TABLE 12 C1 C2 C3 C4 C5 C6 C7 Hours 36 29 31 31 28 24 0% Ethylvan, HPLC .sub.24th

[0228] The hours reported in Table 12 represent the WOM hours needed to achieve a 2.7-2.8% w/w content of Ethylvanillin in the formulations.

[0229] The compounds of formula C1 remained effective for UV radiation protection for an increased duration of from about 50% as compared to known, commercially available COVABSORB (WO 2006/005846) C6 to obtain a substantially equivalent level of protection.

[0230] The compounds of formula C2 remained effective for UV radiation protection for an increased duration of from about 25% as compared to known, commercially available COVABSORB (WO 2006/005846) C6 to obtain a substantially equivalent level of protection.

[0231] The compounds of formula C3 remained effective for UV radiation protection for an increased duration of from about 25% as compared to known, commercially available COVABSORB (WO 2006/005846) C6 to obtain a substantially equivalent level of protection.

[0232] The compounds of formula C4 remained effective for UV radiation protection for an increased duration of from about 30% as compared to known, commercially available COVABSORB (WO 2006/005846) C6 to obtain a substantially equivalent level of protection.

[0233] The compounds of formula C5 remained effective for UV radiation protection for an increased duration of from about 15% as compared to known, commercially available COVABSORB (WO 2006/005846) C6 to obtain a substantially equivalent level of protection.

[0234] When introducing elements of the present disclosure or exemplary aspects or embodiment(s) thereof, the articles “a,” “an,” “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising.” “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements. Although this disclosure has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations. While the preferred variations and alternatives of the present disclosure have been illustrated and described, it will be appreciated that various changes and substitutions can be made therein without departing from the spirit and scope of the disclosure.